Desmopressin in the treatment of patients with defects of platelet function.

[1]  E. Oliva,et al.  Feasibility of a mixed inpatient-outpatient model of peripheral blood stem cell transplantation for multiple myeloma. , 2002, Haematologica.

[2]  R. Fanin,et al.  B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia. , 2002, Haematologica.

[3]  J M Rainey,et al.  Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  G. Remuzzi,et al.  Platelets: an update on diagnosis and management of thrombocytopenic disorders. , 2001, Hematology. American Society of Hematology. Education Program.

[5]  S. Pileri,et al.  Salvage therapy with thalidomide in multiple myeloma patients relapsing after autologous peripheral blood stem cell transplantation. , 2001, Haematologica.

[6]  K. Schulman,et al.  Platelet transfusions: Utilization and associated costs in a tertiary care hospital , 2000, American journal of hematology.

[7]  D. Norfolk,et al.  Pharmacological therapies to minimise platelet transfusion. , 2000, Transfusion science.

[8]  R. Yang,et al.  Human herpesvirus 6 in hematologic diseases in China. , 2000, Haematologica.

[9]  A. Pession,et al.  Acute childhood idiopathic thrombocytopenic purpura: AIEOP consensus guidelines for diagnosis and treatment. Associazione Italiana di Ematologia e Oncologia Pediatrica. , 2000, Haematologica.

[10]  D. A. Steele,et al.  Anti-D immunoglobulin in children with newly diagnosed immune thrombocytopenic purpura: a pilot study. , 2000, Haematologica.

[11]  R. Fanin,et al.  High-dose therapy in multiple myeloma: effect of positive selection of CD34+ peripheral blood stem cells on hematologic engraftment and clinical outcome. , 2000, Haematologica.

[12]  F. Mandelli,et al.  Autologous peripheral blood stem cell transplantation as first line treatment of multiple myeloma: an Italian Multicenter Study. , 2000, Haematologica.

[13]  T. Barbui,et al.  The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto. , 1997, The New England journal of medicine.

[14]  P. Mannucci.  Desmopressin (DDAVP) in the treatment of bleeding disorders: the first 20 years. , 1997, Blood.

[15]  G. Schoch,et al.  A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant. , 1995, Blood.

[16]  P. Mannucci,et al.  Platelet aggregation at high shear is impaired in patients with congenital defects of platelet secretion and is corrected by DDAVP: correlation with the bleeding time. , 1995, The Journal of laboratory and clinical medicine.

[17]  M. Cattaneo,et al.  Role of ADP in platelet aggregation at high shear: studies in a patient with congenital defect of platelet responses to ADP , 1994, British journal of haematology.

[18]  P. Mannucci,et al.  Shear-induced platelet aggregation is potentiated by desmopressin and inhibited by ticlopidine. , 1993, Arteriosclerosis and thrombosis : a journal of vascular biology.

[19]  J. Loscalzo,et al.  Bleeding time prolongation with streptokinase and its reduction with 1-desamino-8-D-arginine vasopressin. , 1990, Circulation.

[20]  P. Mannucci,et al.  Multimeric composition of factor VIII/von Willebrand factor following administration of DDAVP: implications for pathophysiology and therapy of von Willebrand's disease subtypes , 1982 .